MyOme - Breast Cancer

What is our iPRS™ for breast cancer test?

This test combines a person's genetic information with their personal and family history and clinical factors to provide a five-year and lifetime risk estimate for developing breast cancer for individuals who do not have single gene-driven hereditary breast cancer risk.

Explore Our Approach

PRS and Tyrere-Cuzick Assessment diagram

Beyond Single-Gene Detection

Up to 20% of breast cancers have an underlying genetic risk that cannot be detected by single-gene analysis (e.g., BRCA1 and BRCA2 tests).³

Broad Eligible Population

Up to 95% of individuals do not have a single-gene breast cancer condition but may have genetic risk factors detectable by the iPRS test.¹

Reliable Risk Stratification

Up to 6% of those classified as low-risk by clinical model alone were reclassified as high-risk by iPRS. Those women forgo access to life-saving enhanced screening recommendations like breast MRI. ²

Garber J.E., Offit K. Hereditary Cancer Predisposition Syndromes. J. Clin. Oncol. 2005; 23:276 - 292. doi: 10.1200/JCO.2005.10.042
Tshiaba et al., Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification. JCO Precis Oncol. 2023 Feb;7:e2200447. doi: 10.1200/PO.22.00447
Wendt, Camilla, and Sara Margolin. "Identifying breast cancer susceptibility genes–a review of the genetic background in familial breast cancer." Acta Oncologica 58.2 (2019): 135-146.

Clinical risk factor analysis includes

Current Age
Age at Menarche
Age at First Live Birth
Menopausal Status
Hormone Therapy Use/Duration

Body Mass Index
Breast Biopsy History
Family History of Breast Cancer (both lineages)
Breast Density

Who is this test for?

This test is intended for individuals assigned female at birth, aged 18-84 years old. Individuals with a confirmed pathogenic variant in a breast cancer predisposition gene or with a personal history of breast cancer are not eligible for this test.

Test Code

PR41003

(Breast Cancer iPRS, Proactive Health Plus)

PR42009

(Breast Cancer iPRS, Proactive Health)

Turn Around Times

From samples received, most results are delivered in 5 to 6 weeks*.

If you've already had MyOme testing performed, follow-up testing or re-requisitions are typically completed in under 2 weeks, often within just a few days.

Acceptable Sample Types

Blood
Buccal
Saliva

*Turnaround times are provided as estimates and begin once sample(s) are processed at MyOme. Turnaround times may be extended in cases outside of MyOme's control, including delays related to confirmation testing or other unforseen circumstances.

Order a Breast Cancer iPRS test

We make it easy to order an iPRS test to get insights for personalized care decisions.

This test can be ordered as part of the MyOme Proactive Health or MyOme Proactive Health Plus offerings depending on your needs. In addition, it can be ordered by itself.

Proactive Health Plus leverages whole-genome sequencing for comprehensive insights across coding and non-coding regions.

View Technical One-Pager

Proactive Health uses blended genome-exome—offering a cost-effective option for preventative health decisions.

View Technical One-Pager

Interpreting Breast Cancer iPRS Results

Implications for Breast Cancer Screening and Risk Reduction

Guidelines recommend additional risk reduction strategies for individuals at increased risk to develop breast cancer. Those with a >20% lifetime risk should consider an annual breast MRI alongside mammography.¹ Those with a >1.7% 5-year risk should consider endocrine risk reducing medications based on age and menopause status.² Providers should consider a patient's personal and family history when determining the appropriate screening and prevention strategies.

Sample Report Results Guide

Monticciolo D, Newell M, Moy L, et al. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-914. doi: 10.1016/j.jacr.2023.04.002.
Visvanathan K, Fabian C, Bantug E. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019 Nov; 37(33):3152-3165. doi: 10.1200/JCO.19.01472.

Important considerations

The Breast Cancer iPRS test is a screening tool, not a diagnostic test. It does not detect high-risk monogenic variants like those in BRCA1 or BRCA2. Some with high scores won't develop breast cancer, while some with low scores will. Providers should consider personal and family history when assessing genetic testing needs. Genetic counseling or specialist consultation may aid further evaluation.